levofloxacin has been researched along with Joint Diseases in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Arvieux, C; Bellissant, E; Comets, E; Fily, F; Foulquier, JB; Huten, D; Jullien, V; Laviolle, B; Lemaitre, F; Petitcollin, A; Polard, JL; Revest, M; Tattevin, P; Tron, C; Verdier, MC | 1 |
| Abgueguen, P; Ansart, S; Arvieux, C; Asseray, N; Bernard, L; Cormier, H; Dubée, V; Le Moal, G; Legrand, E; Lemarié, C; Mahieu, R; Ramanantsoa, C; Seegers, V | 1 |
| Takahashi, T | 1 |
1 review(s) available for levofloxacin and Joint Diseases
| Article | Year |
|---|---|
Improved Therapeutic Efficacy in Bone and Joint Disorders by Targeted Drug Delivery to Bone.
Topics: Asparagine; Binding Sites; Bone and Bones; Bone Diseases; Drug Delivery Systems; Drug Design; Durapatite; Enzymes; Estradiol; Glutamine; Humans; Hydrolysis; Joint Diseases; Levofloxacin; Oligopeptides; Protein Binding | 2016 |
2 other study(ies) available for levofloxacin and Joint Diseases
| Article | Year |
|---|---|
Development of a dosing-adjustment tool for fluoroquinolones in osteoarticular infections: The Fluo-pop study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bone Diseases, Infectious; Female; Fluoroquinolones; Humans; Joint Diseases; Levofloxacin; Male; Middle Aged; Models, Biological; Monte Carlo Method; Ofloxacin; Prospective Studies; Staphylococcus; Young Adult | 2021 |
The prognosis of streptococcal prosthetic bone and joint infections depends on surgical management-A multicenter retrospective study.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Bone Diseases; Combined Modality Therapy; Debridement; Drug Therapy, Combination; Female; Hip Prosthesis; Humans; Joint Diseases; Knee Prosthesis; Levofloxacin; Male; Prognosis; Prosthesis-Related Infections; Recurrence; Retrospective Studies; Rifampin; Streptococcal Infections; Streptococcus; Streptococcus agalactiae; Treatment Failure; Treatment Outcome | 2019 |